Toward New Therapies
Experts from academia and industry discuss how to create a new, more effective translational neuroscience drawing on novel technology and recent discoveries.
Today, translational neuroscience faces significant challenges. Available therapies to treat brain and nervous system disorders are extremely limited and dated, and further development has effectively ceased. Disinvestment by the private sector occurred just as promising new technologies in genomics, stem cell biology, and neuroscience emerged to offer new possibilities. In this volume, experts from both academia and industry discuss how novel technologies and reworked translation concepts can create a more effective translational neuroscience.
The contributors consider such topics as using genomics and neuroscience for better diagnostics and biomarker identification; new approaches to disease based on stem cell technology and more careful use of animal models; and greater attention to human biology and what it will take to make new therapies available for clinical use. They conclude with a conceptual roadmap for an effective and credible translational neuroscience—one informed by a disease-focused knowledge base and clinical experience.
ContributorsTobias M. Böckers, Thomas Bourgeron, Karl Broich, Nils Brose, Bruce N. Cuthbert, Ilka Diester, Gül Dölen, Guoping Feng, Richard Frackowiak, Raquel E. Gur, Stephan Heckers, Franz Hefti, David M. Holtzman, Steven E. Hyman, Nancy Ip, Cynthia Joyce, Tobias Kaiser, Edward H. Koo, Walter J. Koroshetz, Katja S. Kroker, Robert C. Malenka, Isabelle Mansuy, Eliezer, Masliah, Yuan Mei, Andreas Meyer-Lindenberg, Lennart Mucke, Pierluigi Nicotera, Karoly Nikolich, Michael J. Owen, Menelas N. Pangalos, Alvaro Pascual-Leone, Joel S. Perlmutter, Trevor W. Robbins, Lee L. Rubin, Akira Sawa, Mareike Schnaars, Bernd Sommer, Maria Grazia Spillantini, Laura Spinney, Matthew W. State, Marius Wernig
Hardcover$55.00 X ISBN: 9780262029865 320 pp. | 6 in x 9 in 7 Halftones; 1 B/W; 5 CYMK
Drug discovery for brain disorders has stalled, much to the detriment of people with conditions such as autism, schizophrenia, and Alzheimer's disease. This book, authored by leading experts in the field, provides compelling new ideas and approaches that could reignite progress.
Eric Nestler, MD, PhD
Nash Family Professor, Director, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai
'What is to be done' to revolutionize the scientific understanding, treatment, and prevention of neurodevelopmental, neurodegenerative, and psychiatric disorders? What has been holding us back? What new scientific tools, technologies, and approaches are now at our disposal to find the treatments that our patients and family caregivers deserve? In this thoughtful and thought-provoking book, leaders from a wide range of disciplines in academia and industry offer their perspectives. They do not provide definitive answers. Rather, they permit us to think about old questions in new ways, they lay out many of the tools needed to navigate what has been most elusive scientific frontier, and they call upon us all to advance the scientific fight against brain and behavioral disorders in the most successful, rapid, and impactful way.
Eric M. Reiman, MD
Executive Director, Banner Alzheimer's Institute
The decades surrounding the launching of the new millennium witnessed a revolution in fundamental neuroscience research. This elegantly composed volume enunciates a second revolution—applications to clinical relevant problems. Leading authorities explicate with elegant lucidity how basic neuroscience is yielding new understanding and therapy of the major neurologic and psychiatric disabilities. A must-read book for all who care about the brain.
Solomon H. Snyder, MD
Professor of Neuroscience, Johns Hopkins Medical School
A must-read volume, especially for those, like me, hoping that a very new and exciting chapter in translational neuroscience is emerging. As described in this book, it is built on a solid scientific footing—genetics, neurocircuits, disease biology, validated cellular and animal models, and importantly, a rational data-driven nosology—and will unquestionably deliver a new generation of highly effective medicines for some of the most disabling and fatal of human afflictions.
Steve Paul, MD
President and CEO, Voyager Therapeutics; Founder, SAGE Therapeutics and Tal Medical; former President, Lilly Research Laboratories; former Scientific Director, National Institute of Mental Health